Crossmark Global Holdings Inc. Increases Position in Zoetis Inc. $ZTS

Crossmark Global Holdings Inc. grew its position in Zoetis Inc. (NYSE:ZTS) by 17.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 61,975 shares of the company’s stock after purchasing an additional 9,014 shares during the period. Crossmark Global Holdings Inc.’s holdings in Zoetis were worth $7,798,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. RFG Advisory LLC lifted its holdings in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the last quarter. YANKCOM Partnership lifted its holdings in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in shares of Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after acquiring an additional 85 shares during the last quarter. Beese Fulmer Investment Management Inc. lifted its holdings in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after acquiring an additional 85 shares during the last quarter. Finally, Quest 10 Wealth Builders Inc. lifted its holdings in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $82.80 on Friday. Zoetis Inc. has a twelve month low of $81.10 and a twelve month high of $172.23. The firm’s fifty day simple moving average is $118.49 and its 200-day simple moving average is $123.70. The firm has a market capitalization of $34.83 billion, a price-to-earnings ratio of 13.73, a PEG ratio of 1.28 and a beta of 0.87. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 61.97%. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts forecast that Zoetis Inc. will post 6.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. UBS Group decreased their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Finally, BTIG Research restated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $141.25.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: JPMorgan lowered its price target on Zoetis from $190 to $130, but kept an overweight rating, implying the stock still has meaningful upside from current levels. Benzinga report on JPMorgan target cut
• Neutral Sentiment: Some analysts remain constructive overall, with recent coverage still showing buy/overweight views and price targets well above the current share price, suggesting longer-term confidence despite near-term pressure.
• Negative Sentiment: Zoetis missed Q1 earnings and revenue estimates, which immediately hurt sentiment around the stock.
• Negative Sentiment: The company cut its FY2026 guidance after seeing weaker U.S. companion animal demand and pricing pressure, raising concerns that pet owners are spending less on veterinary care and premium products. Benzinga report on weak pet care demand
• Negative Sentiment: Media coverage described the earnings release as a sharp disappointment, with reports highlighting a steep selloff after investors reacted to the softer outlook.
• Negative Sentiment: Ademi LLP announced a securities fraud investigation into Zoetis, adding another overhang for shares as investors assess potential legal risk.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.